Gary Whale
Patrimonio netto: 251 621 $ in data 31/07/2026
Patrimonio netto: 251 621 $ in data 31/07/2026
Gary Whale is currently Chief Technology Officer at Zura Bio Ltd. since 2023.
Formerly, Dr. Whale was Vice President & Global Head-Technical Operations at Recordati UK Ltd. from 2020 to 2022 and Chief Operating Officer at VHsquared Ltd. from 2018 to 2020.
Education includes undergraduate and graduate degrees from the University of London and a doctorate from The Robert Gordon University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/04/2026 | 46.339 ( 0,05% ) | 251 621 $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ZURA BIO LIMITED | Direttore Tecnico/Scientifico/R&S | 01/03/2023 |
| Società | Posizione | Fine |
|---|---|---|
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services Supplies medicines and medical devices | Direttore Tecnico/Scientifico/R&S | 01/01/2022 |
VHsquared Ltd.
VHsquared Ltd. BiotechnologyHealth Technology Develops antibody domain products against gastro intestinal infectious and immune mediated diseases | Direttore operativo | 01/04/2020 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Robert Gordon University
The Robert Gordon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
VHsquared Ltd.
VHsquared Ltd. BiotechnologyHealth Technology Develops antibody domain products against gastro intestinal infectious and immune mediated diseases | Health Technology |
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services Supplies medicines and medical devices | Distribution Services |
Zura Bio Ltd.
Zura Bio Ltd. BiotechnologyHealth Technology Operates as a multi-asset clinical-stage biotechnology company that focuses on develops novel medicines for immune and inflammatory disorders | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale